Literature DB >> 10861607

Prognostic factors after surgical resection for pancreatic carcinoma.

P Magistrelli1, A Antinori, A Crucitti, A La Greca, R Masetti, R Coppola, G Nuzzo, A Picciocchi.   

Abstract

BACKGROUND AND OBJECTIVES: Surgical resection offers the only potential cure for pancreatic carcinoma. Several recent series have reported an encouraging increase in 5-year survival rate exceeding 20% and have emphasized the importance of patient selection based on reproducible prognostic factors. The impact on survival of demographic, intraoperative, and histopatologic factors are investigated in this study.
METHODS: Seventy-three patients with adenocarcinoma of the pancreas, treated at the Department of Surgery of the Catholic University of Rome during 1988-1998, were retrospectively analyzed. Survival data were reviewed, and potential prognostic factors were compared statistically by univariate and multivariate analyses.
RESULTS: There was no operative mortality, and the morbidity rate was 37%. Actuarial overall and disease-specific survival rates for all 73 patients were, respectively, 27% and 31% at 3 years and 13% and 21% at 5 years, with a median survival time of 16 months. T stage and nodal status significantly affected survival according to univariate analysis (P = 0.0017 and 0.04). An impact on survival, even if not of statistical significance, was shown for other pathologic or intraoperative factors.
CONCLUSIONS: T and nodal stage are the strongest independent predictors of survival. Limited intraoperative transfusion, reduced operative time, and clear margins also may play a role, which requires further confirmation in a larger series. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10861607     DOI: 10.1002/1096-9098(200005)74:1<36::aid-jso9>3.0.co;2-f

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

1.  Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma.

Authors:  Kwang Yeol Paik; Seong Ho Choi; Jin Seok Heo; Dong Wook Choi
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

2.  Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroki Ohge; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

3.  Is perineural invasion more accurate than other factors to predict early recurrence after pancreatoduodenectomy for pancreatic head adenocarcinoma?

Authors:  Thibaut Fouquet; Adeline Germain; Laurent Brunaud; Laurent Bresler; Ahmet Ayav
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

4.  Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Authors:  Nicolas Tsavaris; Christos Kosmas; Helias Skopelitis; Panagiotis Gouveris; Petros Kopterides; Petros Kopteridis; Dioynissis Loukeris; Frantzeska Sigala; Alexandra Zorbala-Sypsa; Evangelos Felekouras; Efstathios Papalambros
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

5.  Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice.

Authors:  J Tepel; O Dagvadorj; M Kapischke; B Sipos; A Leins; B Kremer; H Kalthoff
Journal:  Int J Colorectal Dis       Date:  2005-08-16       Impact factor: 2.571

6.  Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroki Ohge; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2007-11-17       Impact factor: 3.452

7.  Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region.

Authors:  Jerzy Mielko; Wojciech P Polkowski; Danuta G Skomra; Andrzej J Stanisławek; Andrzej M Kurylcio; Elzbieta M Korobowicz
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

8.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

9.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant.

Authors:  Burcu Saka; Serdar Balci; Olca Basturk; Pelin Bagci; Lauren M Postlewait; Shishir Maithel; Jessica Knight; Bassel El-Rayes; David Kooby; Juan Sarmiento; Takashi Muraki; Irma Oliva; Sudeshna Bandyopadhyay; Gizem Akkas; Michael Goodman; Michelle D Reid; Alyssa Krasinskas; Rhonda Everett; Volkan Adsay
Journal:  Ann Surg Oncol       Date:  2016-01-29       Impact factor: 5.344

10.  Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Authors:  Nikolas Tsavaris; Nicolaos Kavantzas; Kostantinos Tsigritis; Ioannis D Xynos; Nikitas Papadoniou; Andreas Lazaris; Christos Kosmas; George Agrogiannis; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aris Polyzos; John Sarantonis; Heracles Tsipras; Gavrilos Karatzas; Alexandros Papalambros; Efstratios S Patsouris
Journal:  BMC Cancer       Date:  2009-07-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.